{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:30:56Z","timestamp":1764174656076,"version":"3.41.2"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Studies in the renal transplant population have suggested calcium\u2010channel blockers (CCBs) may protect against calcineurin inhibitor (CNI)\u2010induced nephrotoxicity. However, this has not been evaluated in the hematopoietic stem cell transplant (HSCT) population. This retrospective study reviews data from 350 consecutive patients who underwent allogeneic HSCT to determine whether amlodipine improved renal outcomes. Subject data included up to one year from CNI initiation. Patients in the amlodipine group (n\u00a0=\u00a0130) received an average of 143\u00a0days treatment with amlodipine and experienced a smaller decrease in creatinine clearance (CrCl) through day 180. At day 30, change in CrCl was \u221217.4\u00a0mL\/min in the amlodipine cohort and \u221233.8\u00a0mL\/min in the control (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). At day 180, change in CrCl was \u221240.9 and \u221250.6\u00a0mL\/min, respectively (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.005). Incidence of hospitalization with acute kidney injury (AKI) was significantly lower in patients receiving amlodipine, 7.7% (10\/132) vs 16.4% (36\/220) (hazard ratio [HR] 0.44; 95% confidence interval [CI] 0.22\u20100.89). Median blood pressure in the amlodipine group remained &lt;132\/78 through day 360. Our data support the use of amlodipine for hypertension in the allogeneic HSCT population and provide evidence suggesting that CCBs protect against CNI\u2010induced nephrotoxicity.<\/jats:p>","DOI":"10.1111\/ctr.13633","type":"journal-article","created":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T06:24:25Z","timestamp":1560061465000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Amlodipine and calcineurin inhibitor\u2010induced nephrotoxicity following allogeneic hematopoietic stem cell transplant"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-1018","authenticated-orcid":false,"given":"Ryan R.","family":"Jensen","sequence":"first","affiliation":[{"name":"Intermountain Healthcare Acute Leukemia, Blood and Marrow Transplant Program LDS Hospital Salt Lake City Utah"},{"name":"Department of Pharmacy LDS Hospital Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regan M.","family":"Healy","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Acute Leukemia, Blood and Marrow Transplant Program LDS Hospital Salt Lake City Utah"},{"name":"Department of Pharmacy LDS Hospital Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clyde D.","family":"Ford","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Acute Leukemia, Blood and Marrow Transplant Program LDS Hospital Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berrie","family":"Child","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Acute Leukemia, Blood and Marrow Transplant Program LDS Hospital Salt Lake City Utah"},{"name":"Department of Pharmacy LDS Hospital Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Majers","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Acute Leukemia, Blood and Marrow Transplant Program LDS Hospital Salt Lake City Utah"},{"name":"Department of Pharmacy LDS Hospital Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Draper","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Acute Leukemia, Blood and Marrow Transplant Program LDS Hospital Salt Lake City Utah"},{"name":"Department of Pharmacy LDS Hospital Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Hasan","sequence":"additional","affiliation":[{"name":"Royal College of Surgeons in Ireland Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daanish","family":"Hoda","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare Acute Leukemia, Blood and Marrow Transplant Program LDS Hospital Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23882"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/357695a0"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1632"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04800908"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.166"},{"issue":"52","key":"e_1_2_8_7_1","first-page":"S70","article-title":"Cyclosporine\u2010induced renal dysfunction in experimental animals and humans","volume":"48","author":"Remuzzi G","year":"1995","journal-title":"Kidney Int"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90355-7"},{"key":"e_1_2_8_9_1","first-page":"F443","article-title":"Effects of ANG II, ETa, and TxA2receptor antagonists on cyclosporine A renal vasoconstriction","volume":"267","author":"Conger JD","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.332"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198409133111103"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021744"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199301000-00007"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.101"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000222767.15100.e4"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.03.058"},{"key":"e_1_2_8_17_1","first-page":"398","article-title":"Calcium antagonists in heart transplant recipients: effects on cardiac and renal function and cyclosporine pharmacokinetics","volume":"9","author":"Legault L","year":"1993","journal-title":"Can J Cardiol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199705270-00012"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199006000-00013"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.13633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ctr.13633","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.13633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:49:05Z","timestamp":1694332145000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.13633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/ctr.13633"],"URL":"https:\/\/doi.org\/10.1111\/ctr.13633","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"type":"print","value":"0902-0063"},{"type":"electronic","value":"1399-0012"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"2019-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13633"}}